Keywords: Merck & Co Suvorexant, Ph III, Insomnia

Merck & Co's suvorexant improved patients' ability to fall asleep and stay asleep

Article | 14 June 2012

Print This

US drug giant Merck & Co (NYSE: MRK) has announced new data from two pivotal Phase III efficacy trials for ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in